LGALS3BP and metabolic dysfunction-associated steatotic liver disease: LGALS3BP has already been used to build multi‐component classifiers for the prediction of NAFLD (Wood et al, 2017) and fibrosis in patients with hepatitis C infection (Cheung et al, 2010).